Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Saturday, July 25, 2026.
Forward PE Ratio (N/A) = Close Price ($259.36) / Consensus Forward EPS ($14.05)
FORWARD PE RATIO
N/A
AbbVie Inc.
Market Cap
$458.11B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| AbbVie Inc. (ABBV) | $458.11B | N/A |
| UnitedHealth Group Incorporated (UNH)vs › | $382.09B | 21.34 |
| Merck & Co., Inc. (MRK)vs › | $323.72B | 47.07 |
| Johnson & Johnson (JNJ)vs › | $634.06B | 22.58 |
| AstraZeneca PLC (AZN)vs › | $262.31B | 16.54 |
| Novo Nordisk A/S (NVO)vs › | $216.72B | N/A |
| Thermo Fisher Scientific Inc. (TMO)vs › | $211.18B | 22.73 |
| Amgen Inc. (AMGN)vs › | $202.95B | 16.84 |
| Abbott Laboratories (ABT)vs › | $179.58B | 18.72 |
| Gilead Sciences, Inc. (GILD)vs › | $160.55B | N/A |
Trailing P/E
127.2
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $14.05 implies +588.7% EPS growth vs the reported trailing $2.04.
At today's $259.36 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $14.05 | $13.85 – $14.54 | 15 | 18.5x |
| 2027-12-31 | $16.44 | $14.97 – $17.73 | 14 | 15.8x |
| 2028-12-31 | $18.39 | $14.58 – $22.16 | 8 | 14.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
